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Background: Treatment of idiopathic membranous nephropathy with nephrotic syndrome is still controversial.
There is currently little known about the clinical use of renal biomarkers which may explain contradictory results
obtained from clinical trials. In order to assess whether IgG-uria can predict the outcome in membranous nephropathy,
we examined the value of baseline EF-IgG in predicting remission and progression of nephrotic syndrome.
Methods: In a prospective cohort of 84 (34 female) idiopathic membranous nephropathy patients with nephrotic
syndrome we validated the ability of the clinically available urine biomarker, IgG, to predict the risk of kidney disease
progression and the beneficial effect of immunosuppression with steroids and cyclophosphamide. The fractional
excretion of IgG (FE-IgG) and α1-microglobulin (FE-α1m), urine albumin/creatinine ratio, and eGFR were measured at
the time of kidney biopsy. Primary outcome was progression to end stage kidney failure or kidney function (eGFR)
decline≥ 50% of baseline. Patients were followed up for 7.2 ± 4.1 years (range 1–16.8).
Results: High FE-IgG (≥0.02) predicted an increased risk of kidney failure (Hazard Ratio, (HR) 8.2, 95%CI 1.0–66.3,
p = 0.048) and lower chance of remission (HR 0.18, 95%CI 0.09–0.38, p < 0.001). The ten-year cumulative risk of
kidney failure was 51.7% for patients with high FE-IgG compared to only 6.2% for patients with low FE-IgG. During
the study, only 24% of patients with high FE-IgG entered remission compared to 90% of patients with low FE-IgG.
Combined treatment with steroids and cyclophosphamide decreased the progression rate (–40%) and increased
the remission rate (+36%) only in patients with high FE-IgG.
Conclusion: In idiopathic membranous nephropathy patients with nephrotic syndrome, FE-IgG could be useful
for predicting kidney disease progression, remission, and response to treatment.
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Idiopathic membranous nephropathy (IMN) is a major
cause of nephrotic syndrome (NS) in adult patients [1]. NS
is associated with an increased risk of kidney failure and
death from cardiovascular causes [2]. IMN is characterised
by subepithelial localisation of IgG immune-complexes
and lack of significant proliferation in the glomerular
tuft. The recent discovery of the podocyte antigen
PLA2R and its corresponding IgG autoantibodies con-
firmed the autoimmune nature of the disease [3].
There is no specific treatment for IMN. Early initiation
of immunosuppressive treatment with steroids and cyclo-
phosphamide has been recommended by some investi-
gators [4,5]. Because of the high rate of spontaneous
remission (about 30%), others suggested an initial con-
servative approach [6,7]. Immunosuppressive treatment
could be harmful, but waiting until the condition starts
to progress carries the risk of missing the “window of
opportunity” for treatment [8-10]. Once this assessment is
made, an individualised treatment based on risk versus
benefit of the immunosuppressive treatment can be
advocated [11].
Nowadays, the severity of kidney disease is com-
monly staged according to the kidney function esti-
mated from serum creatinine (eGFR) [12]. However,
eGFR is not an early predictive marker for treatment
decisions [9]. Therefore, the search continues for early
predictive markers that can estimate the risk of kidney
disease progression. The ideal prognostic biomarker
should be accurate and easy to implement in clinical
practice. Such a biomarker could guide clinical deci-
sions to avoid unnecessary treatment of patients who
are not at risk of progression and to avoid unnecessary
delay in initiation of treatment for those at high risk of
progression to kidney failure.
As in other types of glomerular diseases, the primary
main lesion in IMN is alteration of the glomerular fil-
tration barrier (GFB) function with increased excretion
of albumin (molecular radius, r =36 Å) and high mo-
lecular weight proteins such as IgG (r = 55 Å) and IgM
(r = 120 Å) [13,14]. Thus, increased urine IgG concen-
trations in nephrotic patients could reflect activity and
severity of the glomerulonephritis [13,15,16]. Recent
studies have shown that IgG-uria could provide early
prognostic information for patients with glomerular
disease [13,15,17,18]. However, its value in predicting
the remission and treatment outcome is still unclear.
Using the data from the Milano and Lund glomeru-
lonephritis longitudinal cohorts, we assessed whether
IgG-uria can predict the functional outcome (remis-
sion versus progression) in patients with IMN and NS.
We also evaluated the ability of IgG-uria to identify
patients who might benefit from immunosuppressive
treatment.Methods
Patients
The cohort was derived from patients with IMN and NS
diagnosed between January 1992 and December 2005 at
the Nephrology Unit of San Carlo Borromeo Hospital,
Milan, Italy (n = 70) and the Nephrology Department of
Lund University, Sweden (n = 16). The inclusion criteria
were nephrotic range proteinuria (24-hour proteinuria
≥ 3.5 g, or urinary albumin/creatinine ratio ≥ 2.0 g/g);
serum albumin < 3.0 g/dL; baseline sCr <2.7 mg/dL and
eGFR ≥24 ml/min/1.73 m2). The morphological diagno-
sis was in all cases established by light microscopy and
immunofluorescence staining of representative kidney
biopsy specimens containing at least six glomeruli. One
histo-pathologist in each study center scored semi-
quantitativly the tubulo-interstitial fibrosis as normal
interstitium, focal or diffuse tubule-interstitial fibrosis,
and the percentage of global glomerulosclerosis (GGS)
was calculated. The patients did not have clinical or
laboratory signs of secondary causes of IMN, such as
systemic lupus erythematosus, connective tissue dis-
eases, cancer, or medication with gold or penicillamine.
The collection of 24-hour urine was done the day be-
fore the kidney biopsy, and the blood samples and the
second voided urine specimens were obtained in the
morning of the day of renal biopsy. The study complied
with the Declaration of Helsinki and the local require-
ments for ethical approval (Lund regional ethical com-
mittee: LU 47-02). All patients gave informed written
consent. The baseline characteristics of the cohort are
in Table 1.
Treatment and follow-up
Thirty-five patients were treated only with supportive
therapy, such as diuretics, antihypertensives, angio-
tensin enzyme inhibitors (ACEi/ARBs), statins, anti-
platelet agents, and vitamin D3. Thirty-seven patients,
besides supportive therapy, were treated soon after diag-
nosis with steroids and cyclophosphamide (St + Cyc) for
six months according to the Ponticelli protocol: methyl-
prednisolone 0.5–1.0 g iv for 3 days at the beginning of
months 1, 3 and 5, followed by oral prednisolone 0.5 mg/
kg/day during months 1, 3 and 5, and cyclophosphamide
1–2 mg/kg/day during months 2, 4 and 6 (lower dose of
both drugs for elderly patients and patients with low GFR)
[4]. Twelve patients were treated with steroids alone: five
with prednisone 1 mg/kg/day for 4–12 months, and seven
with ACTH 1–2 mg weekly for 4–11 months. Patients
were followed up until the last planned clinic visit in 2009.
The primary outcome was progression to kidney failure
defined as start of renal replacement therapy (ESRD) or
reduction of eGFR by ≥ 50% of baseline. The secondary
outcome was complete or partial remission of NS (pro-
teinuria < 0.2 or < 2.0 g/day, respectively).
Table 1 Baseline characteristics of patients with idiopathic membranous nephropathy and nephrotic syndrome,
classified according to fractional excretion of IgG
All patients FE-IgG P-value
Low (<0.020) High (≥0.020)
No. of patients 84 40 44
Age (years) 55 ± 16 52 ± 15 58 ± 17 0.07
Sex (M/F) 50/34 20/19 30/15 0.18
eGFR (ml/min/1.73 m2) 72 ± 26 88 ± 20 58 ± 23 < 0.001
eGFR < 60 ml/min/1.73 m2 29 (34%) 5 (13%) 24 (53%) <0.001
BP ≥140/90 mmHg 45 (54%) 13 (34%) 32 (71%) 0.001
Serum albumin g/L 23 ± 6 25 ± 5 22 ± 6 0.02
ACR mg/mmol 373 ± 256 243 ± 278 486 ± 177 < 0.001
FE IgG 0.052 ± 0.063 0.009 ± 0.005 0.090 ± 0.066 < 0.001
FE α1m 0.371 ± 0.409 0.124 ± 0.106 0.601 ± 0.447 < 0.001
GGS (%) 10 ± 14 6 ± 10 13 ± 17 0.02
TIF score 1.3 ± 1.3 0.7 ± 0.7 1.2 ± 0.7 0.08
Follow-up (months) 86 ± 50 98 ± 51 77 ± 48 0.055
ACE inhibitors treatment 50 (60%) 26 (65%) 24 (55%) 0.27
P-values are for the difference between the FE-IgG subgroups.
ACE: Angiotensin converting enzyme; eGFR: estimated GFR; BP: blood pressure; ACR: urinary albumin/creatinine ratio; FE IgG: fractional excretion of IgG; FE α1m:
fractional excretion of α1-microglobulin; GGS: global glomerular sclerosis; TIF: tubulo-interstitial fibrosis.
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A blood sample and a second morning fresh urine
sample were analysed for concentration of creatin-
ine, albumin, IgG and alpha 1 microglobulin in the
chemistry laboratory of Azienda Ospedaliera Ospedale
San Carlo Borromeo, Milan, and in the chemistry labora-
tory of hospital of Lund. Serum creatinine (sCr) and urin-
ary creatinine (uCr) were measured enzymatically and
expressed in μmol/L. Serum and urinary IgG, albumin and
α1-microglobulin (α1m) were measured by immunone-
phelometry method on a BNA nephelometer (Behring,
Milan, Italy) using rabbit serum antihuman antibodies
(Behring) [16], and by immunoturbidimetry using a Cobas
Mira S system (Roche Inc.) [19].
Calculations
Urinary albumin-to-creatinine ratio (mg/g) (ACR) is the ra-
tio of urinary albumin (mg/L) to urinary creatinine (g/L);
fractional excretion of IgG (FE-IgG) and α1m (FE-α1m),
expressed per 100 ml of creatinine clearance, was calculated
according to the formula FE-IgG = (urinary protein/serum
protein) × (serum creatinine/urinary creatinine) × 100.
Glomerular filtration rate (eGFR) was estimated from
serum creatinine using the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-Epi) formula [12].
Statistical analysis
All statistical analyses were performed using IBM SPSS
software version 19.0. Data are expressed as means ±SD. The differences between the study groups were
determined using the Mann-Whitney U test, or the un-
paired t-test as appropriate. Proportions were compared
by Chi-square analysis. Correlations were assessed with
Spearman Rank test. Receiver Operating Characteristic
(ROC) curve was used to determine the cut-off values
for the predictors of kidney failure (Table 2). These
cut-off values were applied to the patients to create
two groups for each predictor - high risk and low risk.
Patients were also divided into high and low eGFR
groups using a cut-off of < 60 ml/min/1.73 m2 accord-
ing to the K/DOQI guidelines. eGFR < 60 ml/min/
1.73 m2 identifies patients with moderate to severe
CKD. The sensitivity and specificity of these cut-off
points were used to calculate the positive likelihood ra-
tio (Table 2). Kidney survival analysis was performed
using the Kaplan–Meier method. Survival time was
calculated from the date of diagnosis. The time horizon
for cumulative kidney survival rate was set at 10 years.
Patients were censored at the time of death or at the
end of follow-up. Patients with missing data were ex-
cluded (2 patients was missing alpha 1 microglobulin ).
Log-rank test was used to assess the difference in sur-
vival. Univariate and multivariate Cox proportional haz-
ards regression analysis was performed on the population
as a whole and on the relevant treatment groups. The
tested dependent variables were FE-IgG, FE-α1m, ACR
and eGFR. Two-sided p <0.05 was considered statisti-
cally significant.
Table 2 Characteristics of receiver operating curves (ROC) for the investigated biomarkers: area under the curves
(AUC), cut-off levels, sensitivity, specificity and likelihood ratio for predicting kidney failure (n 84) and No remission
(n 70) in idiopathic membranous nephropathy patients with nephrotic syndrome
Biomarkers AUC p-value Cut-off Sensitivity % Specificity % Likelihood ratio
Prediction of kidney failure
eGFR 0.27 0.003 60 32 25 0.42
FE IgG 0.77 < 0.001 0.020 95 59 2.3
ACR 0.75 < 0.001 4000 84 56 1.9
FE α1m 0.76 < 0.001 0.240 84 60 2.1
High FE IgG and FE α1m 0.784 <0.001 0.02 + 0.24 84 68 2.6
Prediction of no remission
eGFR 0.26 0.001 60 41 11 0.46
FE IgG 0.82 < 0.001 0.020 91 72 3.3
ACR 0.73 < 0.001 4000 76 69 2.5
FE α1m 0.76 < 0.001 0.240 85 67 2.6
High FE IgG and FE α1m 0.83 <0.001 0.02 + 0.24 82 78 3.7
eGFR: estimated GFR (ml/min/1.73 m2); FE IgG: fractional excretion of IgG; ACR: urinary albumin/creatinine ratio; FE α1m: fractional excretion of α1-microglobulin.
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The fractional excretion of IgG (FE-IgG) was measured in
84 (34 female) patients Table 1. The overall average follow-
up time was 86 ± 50 months (range 12–202). During
follow-up, 20 patients progressed to kidney failure, 14 pa-
tients to ESRD, and 6 patients to eGFR ≤50% of baseline.
FE-IgG was strongly related to the baseline eGFR
(r: –0.654, p = 0.01) and last eGFR (r: –0.570, p = 0.01),
and weakly with global glomerulosclerosis (r = 0.380,
p = 0.001) and tubulo-interstitial fibrosis (r = 0.297,
p = 0.01). The optimal cut-off level for high FE-IgG
was ≥ 0.02, for high FE-α1m ≥ 0.24, and for high ACR ≥
4000 mg/g uCr (Table 2). FE-IgG had a better likelihood
ratio for prediction of kidney failure thanFE-α1m, ACR
or eGFR (Table 2).
The results of univariate Cox-regression analysis are
shown in Table 3. In a multivariate Cox-regression ana-
lysis the association between FE-IgG and progression
to kidney failure remains highly significant even after
adjustment for the key potential confounding factors:Table 3 Univariate Cox regression analysis for outcome of
renal failure in 84 patients with idiopathic membranous
nephropathy and nephrotic syndrome
Variable Beta SE P-value HR 95% CI
ACR (2 groups) 1.88 0.63 0.003 6.58 1.92–22.59
FE IgG (2groups) 3.08 1.03 0.003 21.76 2.90–163.11
FE α1m (2 groups) 2.14 0.64 0.001 8.53 2.46–29.62
eGFR (2 groups) 1.71 0.481 <0.001 5.5 2.14–14.13
Beta = regression coefficient, SE = standard error, HR = hazard ratio, CI = confidence
interval, eGFR = estimated GFR <≥ 60 ml/min/1.73, ACR <≥ 4 g/g, FE-IgG < ≥ 0.020,
FE-α1m<≥ 0.24.age, kidney function, blood pressure, proteinuria, and
treatment with ACEi/ARB and immunosuppression drugs,
(HR 20.84, 95% CI: 2.8–156.8, p =0.003, Figure 1).
Remission of nephrotic syndrome (NS)
Remission rate could be evaluated only for Milano group
of patients (n = 70) (Figure 2). Irrespective of immuno-
suppressive treatment, most patients who had low FE-
IgG went into remission (89.7% of patients at 36 months,
95% CI: 21–51). In contrast, the remission occurred only
in less than a third of patients with high FE-IgG and at a
later time (24.4% of patients at 128 months, 95% CI:
105–151, p <0.001).
FE-α1m groups
The remission was more frequent and earlier in patients
with low FE-α1m (82.8% of patients at 47.1 months, 95%
CI: 27–67 months) than patients with high FE-α1m
(29.3%, at 119.9 months, 95% CI: 96–144, p <0.001).
ACR groups
The remission was more frequent and earlier in patients
with low ACR (75.8% of pats, at 55.1 months, 95%
CI: 33–77), than patients with high ACR (29.7%, at
109.5 months, 95% CI: 86–133, p < 0.001).
eGFR groups
Most of the patients with baseline eGFR ≥ 60 ml/min/
1.73 m2 went into remission (69.6%, at 60.3 months,
95% CI: 41–79) compared to patients with baseline
eGFR < 60 ml/min/1.73 m2 (16.7%, at 142.7 months, 95%
CI: 118–167, p <0.001).
Figure 1 Kidney survival in patients with idiopathic membranous nephropathy and nephrotic syndrome according to FE-IgG levels.
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only FE-IgG as an independent predictor for remission
(HR 0.18, 95% CI, 0.09-0.38, p <0.001) (Figure 2).
IgG fractional excretion and response to treatment
The 37 patients treated with steroids and cyclophos-
phamide were compared with the 35 patients treated
only with supportive therapy. The baseline characte-
ristics of the two groups are in Table 4. There was no
difference in initial kidney function or degree of pro-
teinuria. During the study, the overall rates of progres-
sion to kidney failure in the untreated and treated
patients did not differ significantly (37% vs. 27.6%,
respectively, p = 0.84). However, untreated patients with
high FE-IgG were more likely than treated patients
to progress to kidney failure (72% vs. 43%, respectively,
p =0.014) (Figure 3a). For patients with low FE-IgG
there was no significant difference in risk of progression
to kidney failure between the untreated and treated pa-
tients (12.5% and 0%, respectively, p = 0.39) (Figure 3b).
Untreated and treated patient did not differ in overall
remission rate (51.7% vs. 51.2%, p = 0.7). However, for
patients with high FE-IgG, the remission rate was 0% foruntreated and 36% for treated patients (p = 0.025). There
was no difference in the frequency of remission between
untreated and treated patients with low FE-IgG (93.7%
vs. 84.6%, p = 0.23).
Discussion
This longitudinal cohort study validated the predictive
value of the fractional excretion of IgG in IMN patients
with nephrotic syndrome. The heterogeneity of the pro-
gression to kidney failure in IMN patients and the lack
of a reliable marker of disease severity has been a major
confounding factor that contributed significantly to the
contradictory results of the previous clinical treatment
trials [20]. A recent meta-analysis of 1025 patients en-
rolled in 18 random controlled trials showed an increase
in the likelihood of remission for patients treated with
steroids and alkylating agents, but there were no bene-
ficial effects on kidney function [21]. In our cohort,
immunosuppressive treatment with steroids and cyclo-
phosphamide significantly improved the clinical out-
come only in patients with increased urinary excretion
of IgG (FE-IgG ≥ 0.02). For these patients, immunosup-
pressive treatment reduced the 10-year incidence of
Table 4 Clinical, proteinuric and histologic parameters of
35 idiopathic membranous nephropathy patients with
nephrotic syndrome not treated with immunosuppressive
drugs and 37 others treated with combined steroids and
cyclophosphamide
Untreated Treated p-value
No. of patients 35 37
Age (years) 53 ± 17 56 ± 16 0.65, ns
Sex (M/F) 16/19 26/11 0.034
Baseline eGFR ml/min/1.73 m2 77 ± 27 69 ± 25 0.19, ns
eGFR < 60 ml/min/1.73 m2 34% 32% 0.8, ns
BP ≥140/90 mmHg 52% 51% 0.89, ns
ACR mg/mmol 350 ± 242 379 ± 185 0.57, ns
FE IgG 0.040 ± 0.055 0.067 ± 0.069 0.07, ns
FE α1m 0.325 ± 0.382 0.435 ± 0.411 0.24, ns
GGS (%) 7.7 ± 10.7 11.3 ± 17.7 0.30, ns
TIF score 1.0 ± 0.9 1.4 ± 1.3 0.19, ns
Time to reach ESRD (months) 55 ± 29 90 ± 46 0.07, ns
Legend: eGFR: estimated GFR; ESRD: end stage renal disease; BP: blood pressure;
ACR: urinary albumin/creatinine ratio; FE IgG: fractional excretion of IgG; FE α1m:
fractional excretion of α1-microglobulin; GGS: global glomerular sclerosis; TIF:
tubulo-interstitial fibrosis (0 absent, 1 focal, 2 diffuse), ns = non-significant.
Figure 2 Remission of proteinuria in patients with idiopathic membranous nephropathy and nephrotic syndrome according to
FE-IgG level.
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by 36%. Patients with lower concentrations of urine IgG
(FE-IgG <0.020) went into spontaneous remission more
frequently and maintained kidney function even without
immunosuppressive treatment.
As in previous studies, our cohort showed that impair-
ment of kidney function and increased proteinuria are
associated with faster progression to kidney failure. How-
ever, the fractional excretion of IgG predicts both remis-
sion of NS (HR 0.18) and progression to kidney failure
(HR 8.2) independently from albuminuria and GFR.
The role of albuminuria in the progression of kidney
disease has been questioned in many experimental and
clinical studies. The GFR estimated from serum creatinine
is considered a late sign of the severity of kidney disease
[22,23]. Thus, inclusion of FE-IgG in clinical practice
guidelines may provide a substantial improvement in risk
prediction during the early stages of IMN. It might help
clinicians to individualise treatment and thereby improve
outcome. Patients with high FE-IgG may benefit from
more intensive monitoring of kidney function and from
early initiation of immunosuppressive therapy.
Figure 3 Effect of immunosuppressive treatment on kidney survival in patients with idiopathic membranous nephropathy and
nephrotic syndrome, according to FE-IgG level. a: untreated patients with high FE-IgG were more likely than treated patients to progress to
kidney failure. b: patients with low FE-IgG behaved similarly, progressing slowly to kidney failure.
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various new immunosuppressive treatments, such as
mycophenolate mophetil, tacrolimus, rituximab, and
synthetic ACTH for patients not responding to ste-
roids and alkylating agents [24-28]. It will be of clin-
ical interest to include FE-IgG in future treatment
trials.
The main strength of our study, the possibility of
using a simple, practical renal biomarker that can be
included in routine clinical care for kidney disease pa-
tients, is particularly relevant. Urine IgG measured in a
spot urine sample and calculation of FE-IgG can be in-
tegrated into the routine laboratory investigation in
most clinical laboratories. Nephrotic patients are usu-
ally managed by kidney specialist, and the results of
this study can be generalised among different health
care systems.
Calculating the risk of kidney failure in nephrotic
patients is important for management decisions, and
maintaining kidney function is usually associated with
better survival. Whether immunosuppressive treat-
ment improves patient survival should be addressed in
multicentre longitudinal studies on large numbers of
patients.Conclusions
In conclusion, in idiopathic membranous nephropathy
patients with nephrotic syndrome, urinary excretion of
IgG could be helpful, in addition to albuminuria, for
assessment of the risk of disease progression and response
to treatment. Validation of our results on a large external
cohort and in new clinical trials is warranted.
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